ACRX - AcelRx Pharmaceuticals, Inc.
| Previous Close | 4.18 |
| Open | 4.20 |
| Bid | 0.00 x 27000 |
| Ask | 0.00 x 2900 |
| Day's Range | 3.95 - 4.25 |
| 52 Week Range | 1.55 - 5.75 |
| Volume | 596,233 |
| Avg. Volume | 564,643 |
| Market Cap | 205.282M |
| Beta | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.13 |
- ACCESSWIRE•3 days ago
Neovasc and Three Additional Medical Appliances & Equipment Stocks on Our Research Desk’s Radar
This Monday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), Accuray Inc. (NASDAQ: ARAY), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). All you have to do is sign up today for this free limited time offer by clicking the link below.
- Zacks•6 days ago
Top Ranked Momentum Stocks to Buy for June 15th
Top Ranked Momentum Stocks to Buy for June 15th
- Benzinga•8 days ago
Analyst: AcelRx Will Address FDA Concerns, Secure Approval This Year
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has been slowly recovering from a mid-October plunge following the FDA's issuance of a Complete Response Letter. “Since ACRX obtained a CRL in 2017, the company has addressed the FDA's concerns, and reduced the maximum daily dosage of Dsuvia to 12 doses from 24,” the analyst said.
- Benzinga•9 days ago
Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 11) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
- GlobeNewswire•9 days ago
Detailed Research: Economic Perspectives on Southern, AcelRx Pharmaceuticals, International Flavors & Fragrances, Pandora Media, Express Scripts Holding, and United Continental — What Drives Growth in Today's Competitive Landscape
NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southern ...
- Zacks•16 days ago
Top Ranked Momentum Stocks to Buy for June 5th
Top Ranked Momentum Stocks to Buy for June 5th
- PR Newswire•28 days ago
AcelRx announces FDA acceptance of NDA for DSUVIA
DSUVIA PDUFA date set for November 3, 2018 REDWOOD CITY, Calif. , May 24, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused ...
- PR Newswire•29 days ago
Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures
REDWOOD CITY, Calif., May 23, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that all of AcelRx shares owned by Three Arch Partners III, L.P., Three Arch Associates III, L.P., Three Arch Partners IV, L.P. and Three Arch Associates IV, L.P. (Three Arch or the Funds) were acquired by investors led by Leerink Revelation Partners and Industry Ventures (collectively, the Investors). The Three Arch funds that held the AcelRx shares were each formed between 1999 and 2004 and are at the end of their respective terms. The Funds are in the dissolution process and are each finalizing the liquidation of their entire respective portfolios consisting of the Funds' remaining assets, which included their respective investments in AcelRx, comprised of 9,367,041 shares in the aggregate across all of the Funds. AcelRx did not receive any proceeds from these transactions.
- PR Newswire•last month
AcelRx Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
REDWOOD CITY, Calif. , May 22, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Simply Wall St.•last month
Why You Need To Look At This Factor Before Buying AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
If you are looking to invest in AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
- Thomson Reuters StreetEvents•last month
Edited Transcript of ACRX earnings conference call or presentation 9-May-18 8:30pm GMT
Q1 2018 AcelRx Pharmaceuticals Inc Earnings Call
- ACCESSWIRE•last month
Blog Exposure - AcelRx Pharma Resubmitted New Drug Application for DSUVIA with FDA
LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want access to our free research report on AcelRx Pharma, Inc. (NASDAQ: ACRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ACRX as the Company's latest news hit the wire. On May 09, 2018, the Company announced that the Company has resubmitted the New Drug Application (NDA) with the US Food and Drug Administration (FDA) seeking approval for DSUVIA. Active-Investors.com is currently working on the research report for ABIOMED, Inc. (NASDAQ: ABMD), which also belongs to the Healthcare sector as the Company AcelRx Pharma.
- Associated Press•last month
AcelRx Pharmaceuticals: 1Q Earnings Snapshot
The Redwood City, California-based company said it had a loss of 23 cents per share. The drugmaker posted revenue of $343,000 in the period. In the final minutes of trading on Wednesday, the company's ...
- PR Newswire•last month
AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results
- DSUVIA™ (sufentanil sublingual tablet, 30 mcg) New Drug Application (NDA) resubmitted to U.S. Food and Drug Administration (FDA) - March 31, 2018 cash and short-term investments balance of $51.2 million ...
- Simply Wall St.•last month
Want To Invest In AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)? Here’s How It Performed Lately
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) track record on aRead More...
- ACCESSWIRE•last month
Stocks Under Scanner in the Medical Equipment Space – Accuray and Two more Stock Research Monitor: ACRX, and CHFS
This Wednesday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Accuray Inc. (NASDAQ: ARAY), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and CHF Solutions Inc All you have to do is sign up today for this free limited time offer by clicking the link below. Sunnyvale, California headquartered Accuray Inc.'s stock finished Tuesday's session 3.23% lower at $4.50 with a total trading volume of 429,142 shares.
- PR Newswire•last month
AcelRx resubmits New Drug Application for DSUVIA™
REDWOOD CITY, Calif., May 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the resubmission of the New Drug Application (NDA) for DSUVIA with the U.S. Food and Drug Administration (FDA). AcelRx anticipates that the FDA will acknowledge acceptance of the NDA within 30 calendar days of the resubmission date.
- Simply Wall St.•2 months ago
Best NasdaqGM Growth Companies
Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as AcelRx Pharmaceuticals and Intersect ENT are deemed to be superiorRead More...
- PR Newswire•2 months ago
AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems
REDWOOD CITY, Calif. , April 30, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- PR Newswire•2 months ago
AcelRx receives positive CHMP opinion for DZUVEO™ for management of acute moderate to severe pain in medically monitored settings
REDWOOD CITY, Calif., April 27, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of DZUVEO (known as DSUVIA™ in the U.S.) for the management of acute moderate to severe pain in adults in medically monitored settings. "The CHMP positive opinion recognizes the compelling efficacy and safety profile of DZUVEO and is a significant step forward in bringing a novel, non-invasive medicine that could potentially transform the management of moderate to severe acute pain in medically monitored settings for healthcare systems, providers and patients in Europe," said Vince Angotti, Chief Executive Officer of AcelRx.
- PR Newswire•2 months ago
AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018
REDWOOD CITY, Calif. , April 25, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results ...
- ACCESSWIRE•2 months ago
Blog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIA
LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) ("AcelRx").If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ACRX as the Company's latest news hit the wire. On April 16, 2018, the specialty pharmaceutical Company, which is focused on the development and commercialization of innovative therapies for the treatment of acute pain, declared the successful completion of the human factor study to validate the effectiveness of the revised DSUVIA directions for use (DFU).
- PR Newswire•2 months ago
AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting
REDWOOD CITY, Calif. , April 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- PR Newswire•2 months ago
AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
REDWOOD CITY, Calif. , April 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in ...
- PR Newswire•2 months ago
AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe
REDWOOD CITY, Calif., April 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported the publication of a report commissioned by AcelRx analyzing the economic burden associated with administration of intravenous (IV) morphine for acute pain in the emergency department (ED) in the peer-reviewed journal Drugs in Context. This manuscript reports on the results of a micro-costing analysis to estimate the burden of IV administration of morphine in five key European countries based on a literature review.
